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Abstract 
 
We compared post-relapse overall survival (OS) after autologous-allogenenic (auto/allo) versus 
tandem autologous (auto/auto) hematopoietic cell transplantation (HCT) in multiple myeloma 
(MM). Post-relapse survival of patients receiving an auto/auto or auto/allo HCT for MM and 
prospectively reported to the Center for International Blood and Marrow Transplant Research 
(CIBMTR) between 2000 and 2010 were analyzed. 404 patients (72.4%) relapsed in the 
auto/auto group and 178 patients (67.4%) relapsed in the auto/allo group after a median follow 
up of 8.5 years. Among auto/allo patients, 46% of relapses occurred in < 6 months from 2nd 
HCT, compared to 26% in the auto/auto group. The 6 year post-relapse survival of the auto/allo 
group (44%) was superior compared to auto/auto group (35%) (p=0.05). 101 patients in 
auto/allo patients died due to MM (69%) vs. 229 (83%) deaths in auto/auto group. In multivariate 
analysis, both cohorts had a similar risk of death in the 1st year after relapse (hazard ratio (HR) 
of 0.72; p=0.12). However, for time points beyond 12 months after relapse, patients in the 
auto/allo group had superior OS compared with auto/auto cohort (HR for death in auto/auto 
=1.55; p=0.005). Other factors associated with superior survival were enrollment in a clinical trial 
for HCT, male sex and novel agent use at induction before HCT. Survival after relapse is 
superior in auto/allo HCT recipients compared to auto/auto HCT recipients. This likely reflects 
an improved response to salvage therapy, such as immunomodulatory drugs, potentiated by 
donor-derived immunologic milieu. Further augmentation of post-allotransplant immune system 
with new immunotherapies such as monoclonal antibodies, check point inhibitors and others 
should be studied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Introduction 
 
The survival of patients with multiple myeloma (MM) has improved significantly over the past 
two decades.1 High-dose chemotherapy with autologous hematopoietic cell transplantation 
(HCT) improves survival compared with conventional chemotherapy or novel agents.2,3 
However, despite high remission and survival rates, the risk of progressive disease remains a 
concern after both single and tandem HCT.4 
Allogeneic HCT, which provides a tumor-free graft, has been considered as an alternative 
treatment with curative potential for patients with myeloma. The potential long term benefit is 
attributed to the graft-versus-myeloma (GVM) effect, best demonstrated by higher molecular 
remissions after donor lymphocyte infusions.5 Early studies evaluating allogeneic HCT with 
myeloablative conditioning regimens demonstrated improved molecular remissions and lower 
rates of relapse, but were hindered by high treatment-related mortality.6 More recently, the 
combination of autologous transplant followed by reduced intensity allogeneic transplant 
appears to retain the potent GVM effect while reducing treatment-related mortality (TRM).7 
To date, five large prospective trials8-13 involving approximately 1600 patients have shown a lack 
of overall survival (OS) advantage with the auto/allo HCT approach, while two trials14-16 involving 
approximately 500 patients have demonstrated a survival benefit. Differences in outcome can 
be attributed to differences in study design, including the target population, conditioning 
regimen, sibling donor availability, and length of follow up (Supplemental Table 1). Two 
published meta-analysis also did not show an OS benefit for auto/allo over auto/auto HCT.17,18 
In the largest trial by Krishnan et al,12 outcomes of 710 MM patients receiving auto/allo HCT 
(226 patients, low dose total body irradiation conditioning for allo HCT) vs. tandem auto HCT 
(484 patients) by biological assignment (based on availability of human leukocyte antigen 
(HLA)-matched sibling donor) were compared. There was no significant difference in 3-year 
progression free survival (PFS)/OS between auto/allo HCT and tandem auto-HCT group (PFS: 
43% vs. 46%, p= 0.671 and OS: 77% vs. 80%, p=0.191). A criticism of the study was the follow 
up time of 36 months, which was thought to be too short to reveal the possible favorable effects 
of an allo HCT. One of the unanswered questions of this trial as well as other auto/allo HCT 
trials is not only comparisons of PFS with tandem auto-HCT vs auto/allo HCT with longer follow- 
up, but also the long term impact of these treatment modalities. Since these trials used 
transplant in the upfront setting, patients had many treatment choices at the time of relapse. 
 
 
  
 
 
 
 
 
Most of the trials above measured OS from the time of transplant and there have been reports 
of OS for MM in CIBMTR population after alloHCT 20, 29. Gahrton, et al. have demonstrated that 
survival after relapse was superior in the auto/allo recipients compared with auto/auto HCT. 16 
We therefore conducted a retrospective analysis to study the outcome of patients who relapse 
after auto/allo HCT versus auto/auto HCT. 
Patients and Methods 
Patients 
There were 1679 patients who either received an upfront auto/auto (n=1186) or auto/allo HCT 
(n=569) for MM reported to the CIBMTR between 2000 and 2010 in North America. We 
excluded patients who had relapsed between the 2 transplants. Patients who received their 2nd 
transplant later than 6 months after 1st transplant were also excluded. After exclusion, there 
were 558 patients in auto/auto group and 264 patients in auto/allo group remained for further 
analysis. We studied patients who either relapsed or progressed and the term “relapse” in this 
analysis will represent both relapsed and progressive disease categories. Detailed eligibility 
criteria are shown in Figure 1 and Supplemental table 2. For allo HCT, we selected only 
peripheral blood stem cell source. High risk myeloma was defined as del17p, t(4;14), t(14;16), 
hypodiploidy (<45 chromosomes excluding -Y) or chromosome 1 p and 1q abnormalities.19 
Statistical analysis 
 
We compared post-relapse OS between auto/allo HCT cohort versus the auto/auto HCT cohort. 
Our secondary objective was to identify factors associated with long term survival after tandem 
transplantation (auto/allo or auto/auto). 
We tested differences between the patient groups using the chi-square test and Kruskal-Wallis 
test for categorical and continuous variables, respectively. For univariate analyses, survival 
probabilities were calculated by using the Kaplan-Meier estimator with the variance estimated 
by Greenwood’s formula. 
 
Post-relapse survival was defined as the interval between first progression or relapse after 
completion of HCT and death with survivors censored at last follow up. Multivariate analysis of 
post-relapse OS was conducted using the Cox proportional hazards regression model. The 
transplant group, auto/auto versus auto/allo, was considered as the main effect. Other factors 
tested included age at 1st transplant, gender, Karnofsky performance status (KPS) at 2nd 
transplant, clinical trial enrollment, advanced stage at diagnosis (International Staging System III 
  
 
 
 
 
 
or Durie Salmon Stage III), lines of pre-transplant chemotherapy, pre-transplant novel 
(thalidomide, lenalidomide, bortezomib, pomalidomide and carfilzomib) therapy use, time from 
diagnosis to 1st transplant, disease status prior to 2nd transplant and time from 2nd transplant to 
relapse. All statistical tests were two-sided with a significance level of 5%. 
 
Results 
 
404 patients (72.4%) relapsed in the auto/auto group and 178 patients (67.4%) relapsed in the 
auto/allo group. The baseline characteristics of relapsed patients are shown in table 1. 
Patient Characteristics 
 
The majority of patients were male (58 % auto/allo and 60% in auto/auto group). The median 
age was lower in auto/allo patients at 51 years and 56 years in auto/auto group. The majority of 
patients had a KPS of ≥90% (71% and 60% for auto/allo and auto/auto, respectively). Five 
percent of patients in both groups were high-risk by cytogenetics, though data were missing in 
35% of patients. 
Transplant-related  characteristics 
 
1st transplant-related characteristics 
 
73% of auto/allo patients and 90% of auto/auto patients received 1-2 lines of therapy before 
their 1st transplant indicating that the cohorts in this study were less heavily pretreated. The use 
of novel agents at induction was higher in auto/auto group (73%) versus the auto/allo group 
(58%) (p=<0.001). The incidence of partial response or higher (≥PR) before 1st HCT was also 
higher in auto/auto group (88%) than auto/allo group (82%) (p < 0.001). The majority of patients 
received melphalan at 200 mg/m2 at first transplant in both groups. The median time from 
diagnosis to 1st HCT was 8 months in auto/allo group and 7 months in auto/auto patients again 
reflecting the upfront use of HCT in these cohorts. 
2nd transplant-related characteristics 
 
The complete response (CR) rate before the 2nd HCT was 19% and 14% in auto/allo and 
auto/auto group, respectively. The 2nd HCT was done within 3 months of the 1st HCT in 39% of 
patients in auto/allo group and 29% in auto/auto group. 
In the auto/allo group, the majority of the patients (96%) received HLA-matched donor grafts 
and matched unrelated donors represented only 4% of the group. Almost all patients who 
received auto/allo HCT were conditioned with myeloabalative regimen (table 1). Cyclosporine 
  
 
 
 
 
 
and mycophenolate mofetil were the most commonly used drugs for graft vs. host disease 
(GVHD) prophylaxis in 65% of the auto/allo group. 
There were 18 patients who received donor lymphocyte infusion (DLI) and only one patient 
received DLI as a planned therapy and remaining 17 patients received DLI for relapse after 
allogeneic transplant. The patients who received DLI didn’t have superior OS compared to 
patients who didn’t receive DLI (Supplemental table 3). 
Post 2nd transplant outcomes 
 
28.7 % of patients in the auto/auto group received some form of maintenance chemotherapy as 
opposed to 8.8 % in auto/allo group (p<0.001). In the auto/allo cohort, the incidence of grade II- 
IV acute GVHD (aGVHD) was 24 % and grade III-IV was 11%. 58% of patients developed 
chronic GVHD (cGVHD). The median follow up time from relapse was 102 months for auto/allo 
and 99 months for auto/auto group, respectively. High proportion of patients (46%) relapsed 
within 6 months after auto/allo HCT but only 26% of auto/auto patients relapsed in the same 
time frame. There were more relapse in auto/auto group (39%) than auto/allo patients (24%) 2 
years after 2nd HCT. 
 
 
Post-relapse OS 
 
In univariate analysis, the 6 year probability of survival in auto/allo group was 44% compared to 
35% in auto/auto group (p=0.05). (Table 2). 
After a median follow up of 102 months, 101 patients in the auto/allo group had died, 70 patients 
(69 %) were due to myeloma and 4 patients (4%) from GVHD (Table 3). 16 patients (16%) died 
due to infections in auto/allo patients compared to 8 patients (3%) in auto/auto patients. In the 
auto/auto group, 229 patients died after median follow up of 99 months, 189 patients (83%) 
were due to MM. TRM was 6% in auto/allo group and 1% in auto/auto group at 1 year 
(Supplemental table 4). 
The median survival from diagnosis to death for auto/allo patients group was 86.3 months (11.4- 
183.8) vs. 75 months (10.9-173.3) in auto/auto group. Similarly OS probability at 7 years from 
diagnosis were 55.7 % in auto/allo group and it was 51.3% (p=0.33) in tandem auto group. 
 
 
 
 
  
 
 
 
 
 
On multivariate analysis, a pattern of differential time-dependent risk of mortality was observed. 
Both cohorts had a similar risk of death in the 1st year after relapse (HR of 0.72; p=0.12). 
However, beyond 12 months post-relapse, patients in the auto/allo group had a superior OS 
compared with auto/auto cohort (HR for death in auto-auto=1.55; p=0.005) (Table-4).Significant 
co-variates associated with superior post-relapse survival included enrollment in a clinical trial 
for HCT (HR for death in patients not on trial= 1.39; p=0.005), male sex (HR for death in female 
patients= 1.27; p=0.03) and the use of novel agent/s in pre-transplant chemotherapy (HR of 
death for non-novel agent therapy=1.43; p=0.0023) (Table 4). 
When OS was adjusted using statistically significant variables from multivariate analysis (i.e. 
differential time effect of 12 months, sex, clinical trial enrollment and novel agent use), the 
probability of OS was higher for auto/allo patients (45%) than auto/auto patients (35%) at 6-year 
after relapse (p=0.035) (Supplemental table 5). Figure 2 represents graphic presentation of 
adjusted post-relapse survival. 
Discussion 
 
In this large retrospective registry study analyzing long term post-relapse survival among MM 
patients who underwent auto/auto versus auto/allo HCT, we found that patients who underwent 
auto/allo HCT had a long term post relapse survival advantage beginning after 12 months post - 
relapse. Similar findings which were initially reported by Gahrton et al.16 in allogeneic HCT with 
matched sibling donors are confirmed in our data using a larger real world population of related 
and unrelated grafts. 
Clinical trial enrollment was also found to have positive effect on OS, possibly due to better 
patient selection and closer monitoring. Novel agent therapy at induction also decreased risk of 
death compared to standard chemo therapy. In multivariate analysis of OS, male sex was found 
to have reduced risk of death but age was not found to have significant impact on survival. The 
median age for auot/allo group is younger (51 vs. 56) compared to auto/auto group. It is 
probably due to selection bias to choose younger patients by the treating physicians to proceed 
with auto/allo HCT. The median age for auto/allo group is also younger compared to auto/auto 
group in largest randomized auto vs. allo HCT trial reported by Krishnan et al.12 
CR rate after first HCT were lower in our study compared to auto vs. allo HCT trial reported by 
Krishnan et al12 which may indicate a bias toward doing a 2nd HCT among patients with 
suboptimal CR rates to 1st HCT.Benefit for allogeneic HCT generally takes time to be observed, 
 
  
 
 
 
 
 
as seen in the European Blood and Marrow Transplant study15,16 which showed no significant 
difference in the groups at three years but follow up at five and eight years demonstrated the 
advantage of allogeneic HCT. Our analysis, with a median follow up time of 102 months (8.5 
years) after relapse confirms a statistically significant adjusted survival benefit for the allogeneic 
cohort versus tandem autologous HCT (p=0.035) (Supplemental Table5). 
Almost half the relapses (46%) in the auto/allo group happened early i.e. within six months after 
the second HCT, versus one quarter of the relapses (26%) in the auto/auto group. This was in 
spite of the fact that 90% of patients in both group achieved ≥PR or better before 2nd HCT. The 
difference is likely secondary to the reduced intensity conditioning (RIC) for allo HCT which 
relies on donor lymphocyte effect (that may take up to a year to fully develop) to prevent 
relapses vs. myeloablative conditioning (73% of patients received 200mg/m2 of melphalan) in 
the auto/auto group. Selection bias by treating physicians to enroll MM patients with more 
aggressive/higher risk disease could have been a factor contributing to higher relapses in 
auto/allo patients. Similar early relapses post-allogeneic HSCT were also noted in other 
studies.12,20,21 In addition, a higher usage of post-transplant maintenance therapy in the 
auto/auto patients (28.7% vs. 8.8%) could have played a role in delaying early relapse post auto 
transplant vs. post allo transplant. Lower usage of maintenance therapy especially after auto 
HCT reflects the era of our study (2000-2010) when the maintenance therapy was not 
commonly used. 
The Incidence of cGVHD seems to be higher in our trial (58%) compared to findings from 
others20,22 but we were unable to evaluate the effect of cGVHD on post relapse survival as 
cGVHD is a time-dependent covariate starting at the time of transplant and our study starts from 
time of relapse. We do note that 24% of our patients had history of grade II-IV aGVHD; 
presumably, aGVHD predated the relapse after allogeneic HCT as the median time to relapse 
was 9 months. 
Our study focused on patients who received their allogeneic HCT as a tandem approach after a 
prior auto HCT within six months after first transplant. We excluded patients undergoing allo 
HCT for relapse after an auto HCT. The median interval between diagnosis and first HCT was 
seven months in the auto/allo group. The overwhelming majority of allo HCT donors in our study 
were HLA-matched siblings (96%). The study population of auto/allo HCT matches a better risk 
group identified by CIBMTR review of 1207 patients who underwent allogeneic HCT from 1989 
to 2005 which showed that both factors (>24 months interval between diagnosis to allogeneic 
HCT and unrelated donor graft) are poor prognostic indicators for survival.20 
  
 
 
 
 
 
A major limitation of our study was our inability to measure the significance of high-risk 
cytogenetics which contributed only 5% of study population while approximately 35% of 
cytogenetic data were missing. This is representative of the time period in our study and the 
evolution of what constitutes high-risk cytogenetics in MM over time. Additionally, we do not 
have other potentially relevant factors such as details on salvage therapy and response to 
salvage therapy after relapse following 2nd HCT as they were not regularly reported to the 
database. The important strength of our study is that it included a large number of patients and 
multiple transplant centers reflecting realistic view of outcomes after tandem autologous or 
allogeneic transplantation. 
Allogeneic HCT in MM has evolved over time. Myeloablative transplants have been replaced by 
RIC to reduce treatment related mortality while maintaining GVM effect. Immunomodulatory 
drugs such as lenalidomide can potentiate immunologic effects of allogeneic donor cells as 
seen by the high rate of development of GVHD in the HOVON 76 trial.23 Lenalidomide was also 
used in the EBMT NMAM 2000 study for progressive disease after alloHCT wherein it was first 
noted that the post-relapse OS was superior in auto/RIC allo compared to auto/auto transplant 
group.16 It is thus possible that an improved response to salvage therapy may occur in a donor- 
derived immunologic milieu that is potentiated by the immune effects of agents such as 
lenalidomide and pomalidomide. As noted by Wolschke et al,24 post-alloHCT lenalidomide 
induces both NK and T cell mediated antimyeloma activity. Kneppers et al,23 also showed that 
post-alloHCT lenalidomide increased the frequency of HLA-DR + T cells indicating T cell 
activation. In addition, substantial increase in NK cells displaying activated phenotype indicating 
postallograft immunemodulation is feasible. The role of DLI as a form of immune manipulation 
postallograft relapse and its efficacy in MM is well established25 and Kroger, et al26 have 
pioneered the use of donor lymphocytes and novel agents to potentiate the immune effect of 
allografts in order to augment myeloma responses.Our study indicated early relapses in 
immediate post allo HCT setting. One of the ongoing trials for high risk MM patients, BMT CTN 
1302 (NCT02440464) includes Bortezomib to the conditioning regime and uses ixazomib vs. 
placebo as a maintenance after an allo HCT to evaluate whether such treatment can reduce 
relapse. With the availability of other agents that modulate immune mediated disease control 
such a daratumumab (reduction in T and B regulatory subsets)27 and checkpoint inhibitors,28 
we hypothesize that post-alloHCT immune manipulation can further augment GVM immune 
effects and should be studied in clinical trials. Finally, the early relapse after allo HCT in our 
study also demonstrates that immunologic effect against MM may take time to occur and early 
immune manipulation after transplant may be a logical design in future clinical trials.  
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Figure 1. Overview of patient selection criteria 
 
 
 
 
 
 
 
  
 
 
 
 
Auto, autologous; Allo, allogeneic; CIBMTR, Center for International Blood and Marrow Transplantation Research; 
HCT, hematopoietic stem cell transplantation; MUD, matched unrelated donor 
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Figure 2. Adjusted post-relapse overall survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Table 1. Baseline characteristics of patients who relapsed after auto/allo or auto/auto 
HCT 
 
Variable Auto/allo Auto/auto P-value 
Number of patients 178 404  
Number of centers 51 63  
Patient-related    
Age at 1st HCT, years   <0.001 
Median (range) 51 (29-69) 56 (23-70)  
< 45 38 (21) 49 (12)  
45-60 119 (67) 248 (61)  
61-70 21 (12) 107 (26)  
Gender   0.66 
Male 104 (58) 244 (60)  
Female 74 (42) 160 (40)  
Race   0.002 
Caucasian 126 (71) 308 (76)  
Others 37 (21) 85 (21)  
Missing 15 (8) 11 (3)  
Karnofsky Score at 2nd HCT   0.05 
>= 90% 126 (71) 244 (60)  
< 90% 37 (21) 111 (27)  
Missing 15 (8) 49 (12)  
Clinical trial enrollment 
  
0.25 
Yes 98 (55) 243 (60)  
No 80 (45) 161 (40)  
Disease-related    
Immunochemical subtype at diagnosis   0.14 
IgG 116 (65) 226 (56)  
IgA 27 (15) 98 (24)  
Light chain 26 (15) 65 (16)  
Non-secretory 2 (1) 6 (1)  
Others 4 (2) 6 (1)  
Unknown type 3 (2) 3  
ISS/DS risk at diagnosis   0.18 
Stage III 111 (62) 228 (56)  
Stage I-II 64 (36) 159 (39)  
Missing 3 (2) 17 (4)  
Cytogenetics risk*   0.07 
High risk 9 (5) 21 (5)  
Standard risk 107 (60) 280 (69)  
Missing 62 (35) 103 (25)  
1st transplant-related    
Lines of chemotherapy prior to 1st HCT   <0.001 
1 80 (45) 248 (61)  
2 49 (28) 116 (29)  
3+ 19 (11) 35 (9)  
Missing 30 (17) 5 (1)  
Chemotherapy prior to 1st HCT#   <0.001 
VTD/VRD/VCD 36 (20) 74 (18)  
 
  
 
 
 
 
 
 
 
Variable Auto/allo Auto/auto P-value 
TD,RD,VD 68 (38) 219 (54)  
VAD or others 33 (19) 106 (26)  
Missing 41 (23) 5 (1)  
Conditioning regimen for 1st HCT   <0.001 
Melphalan 130 (73) 393 (97)  
Melphalan + Amifostine 3 (2) 3 (1)  
Melphalan + Topotican 1 (1) 0  
Missing 44 (24) 8 (2)  
Melphalan only 128 (72) 393 (97)  
Others 9 (4) 8 (2)  
Missing 41 (23) 3(1)  
Disease status prior 1st HCT   <0.001 
CR 12 (7) 35 (9)  
PR 133 (75) 321 (79)  
SD/MR 18 (10) 44 (11)  
REL/PROG 2 (1) 4 (1)  
Missing 13 (7) 0  
Time from diagnosis to 1st HCT   0.09 
Median (range) 8 (4-51) 7 (4-147)  
< 6 months 44 (25) 138 (34)  
6 - 12 months 111 (62) 213 (53)  
12 - 24 months 16 (9) 42 (10)  
Time from 1st Chemo to 1st HCT   0.09 
Median (range) 7 (2-58) 6 (1-76)  
< 6 months 58 (32) 182 (45)  
6-12 months 99 (55) 194 (48)  
12-24 months 12 (7) 22 (5)  
> 24 months 6 (3) 6 (1)  
Missing 3 (2) 0  
Year of 1st HCT   <0.001 
1999 1 (<1) 1 (<1)  
2000 5 (3) 8 (2)  
2001 11 (6) 2 (<1)  
2002 8 (4) 3 (<1)  
2003 9 (5) 6 (1)  
2004 44 (25) 81 (20)  
2005 31 (17) 134 (33)  
2006 42 (24) 92 (23)  
2007 18 (10) 35 (9)  
2008 4 (2) 24 (6)  
2009 5 (3) 11 (3)  
2010 0 7 (2)  
2nd transplant-related 
   
GVHD prophylaxis    
TAC + MMF +- other(s) 16 (9)   
TAC + MTX +- other(s) 18 (10)   
CSA + MMF +- other(s) 115 (65)   
 
 
  
 
 
 
 
 
 
Variable Auto/allo Auto/auto P-value 
CSA + MTX +- other(s) 9 (5)   
Others/Missing 20 (11)   
Donor type for ALLO    
HLA-matched related 170 (96)   
HLA-matched unrelated 8 (4)   
Melphalan dose for 2nd AUTO 
HCT(mg/m2) 
   
Low dose-140  94 (23)  
High dose-200  296 (73)  
Unknown  14 (3)  
Disease status prior 2nd HCT   0.27 
CR 33 (19) 56 (14)  
PR 125 (70) 308 (76)  
SD/MR 20 (11) 40 (10)  
Time from diagnosis to 2nd HCT 10.8 (4.9-53.3) 10.9 (6.5-152.2)  
months    
Time from 1st HCT to 2nd HCT   0.03 
< 3 months 69 (39) 119 (29)  
3-6 months 109 (61) 285 (71)  
Conditioning for ALLO HCT 
   
Myeloablative 2 (1)   
Reduced Intensity 153 (86)   
Missing 23 (13)   
 
DLI post 2nd HCT (for ALLO)   
No 160 (90)  
Yes 18 (10)  
Post-transplant maintenance therapy  <0.001 
Novel agents 14 (7.8) 108 (26.8) 
Other agents (steroids, 
Cytoxan) 
2 (1) 8 (1.9) 
None 107 (60) 154(38.1) 
Missing 55 (31) 134(33.1) 
aGVHD II-IV for ALLO relapse  <0.001 
Yes 42 (24)  
No 134 (75)  
Missing 2 (1)  
aGVHD III-IV for ALLO relapse  <0.001 
Yes 19 (11)  
No 156 (88)  
Missing 3 (2)  
cGVHD for Allo HCT relapse  0.04 
Yes 103 (58)  
No 75 (42)  
Time from 2nd HCT to relapse, months  0.01 
Median (range) 9 (0.10-98) 18 (0.13-112) 
< 6 81 (46) 105 (26) 
6-12 21 (12) 45 (11) 
12-24 33 (19) 96 (24) 
 
 
  
 
 
 
 
 
 
> 24 43 (24) 158 (39) 
Median follow-up of survivors (range), 
months 
102 (15-171) 99 (7-137) 
 
 
 
AUTO, autologous; ALLO, allogeneic; HCT, hematopoietic stem cell transplantation; ISS, International Staging 
System; DS, Durie-Salmon; Novel agents include thalidomide, lenalidomide, bortezomib, pomalidomide and 
carfilzomib; V= Velcade (Bortezomib), T=Thalidomide, R= Revlimid (Lenalidomide), C= Cytoxan, D= Dexamethasone, 
VAD, vincristine, Adriamycin, and dexamethasone; CR, complete response; PR, partial response; SD, stable disease; 
MR, minor response; REL/PROG, relapse/progression; TAC, tacrolimus; MTX, methotrexate; MMF, mycophenolate 
mofetil; CSA, cyclosporine; HLA, human leukocyte antigen; DLI, donor lymphocyte infusion; aGVHD=acute graft vs. 
host disease, cGVHD=chronic graft vs. host disease 
 
* High risk myeloma was defined as del17p, t(4;14), t(14;16), hypodiploidy (<45 chromosomes excluding -Y) or 
chromosome 1 p and 1q abnormalities. 
 
# Supplemental table 6: Novel agents used for induction chemo before 1st HCT 
 
 Supplemental table 7: Post transplant maintenance therapy 
 
 
 
 
 
 
Table 2. Post-Relapse survival of patients who relapsed post tandem transplant 
(Univariate Analysis) 
 
 
Auto/allo (N = 178) Auto/auto (N = 404)  
Outcomes  N Eval Prob (95% CI)  N Eval Prob (95% CI) p-value† 
Overall survival post 
relapse 
 
178 
  
403 
 
0.14‡ 
1-year   78 (72-84)%   84 (80-87)% 0.13 
2-year 
  
69 (62-76)% 
  
67 (62-72)% 0.59 
3-year 
  
59 (52-67)% 
  
55 (50-60)% 0.36 
4-year   54 (46-62)%   46 (41-51)% 0.09 
5-year 
  
48 (40-56)% 
  
41 (35-46)% 0.13 
6- year 
  
44 (37-52)% 
  
35 (29-40)% 0.05 
† Pairwise comparison p-value 
‡ Log-rank test p-value 
AUTO, autologous; ALLO, allogeneic; N, number, Prob, probability; CI, confidence interval  
 
 
  
 
 
 
 
 
Table 3. Cause of death of patients who relapsed post tandem transplant 
 
 
Cause of Death Auto/allo (n=178) Auto/auto (n=404) 
Number of death 101 229 
Primary disease 70 (69) 189 (83) 
GVHD 4 (4) 0 
Infection 16 (16) 8 (3) 
Organ failure 4 (4) 9 (4) 
Hemorrhage 0 2 (1) 
Unknown 7 (7) 21 (9) 
AUTO, autologous; ALLO, allogeneic; GVHD, graft-versus-host disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Table 4. Multivariate analysis of OS from relapse in patients who relapsed post tandem 
transplant 
 
 
Effect  Hazard 
Ratio 
95% CI Pairwise 
p-value 
Overall 
p-value 
 
 
Type of 
transplant 
≤12 months 
after relapse 
auto/allo 1   0.0040 
auto/auto 0.72 (0.47,1.087) 0.12  
>12 months 
after relapse 
auto/allo 1    
auto/auto 1.55 (1.14,2.11) 0.0052  
 
Sex 
Male 1    
Female 1.27 (1.02,1.58) 0.030  
 
Clinical trial enrollment 
Yes 1    
No 1.39 (1.11,1.75) 0.0051  
 
 
Induction Chemotherapy 
Novel 
Agent 
1   0.017 
VAD/Others 1.43 (1.12,1.71) 0.0023  
Missing 1.15 (0.73,1.79) 0.54  
CI, confidence interval; VAD, vincristine, Adriamycin and dexamethasone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
